SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Last trade$2.83
Day change-$0.08 (-2.75%)
Day range$2.73 – $2.93
Volume97,437
Market cap$29M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$28.96M
Price / earnings
—
Price / book
0.49×
Price / sales
1.53×
EV / sales
1.1×
EV / EBITDA
-0.87×
Profitability
Earnings per share
-$1.01
Return on assets
-14.87%
Return on equity
-17.11%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
7.57×
Quick ratio
7.57×
Cash ratio
1.24×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$12.05M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SCYX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$235K
$0
$18.65M
$334K
$1.36M
$257K
$977K
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$235K
$0
$18.65M
$334K
$1.36M
$257K
$977K
Selling, general and administrative
$3.56M
$4.12M
$4.59M
$3.58M
$3.29M
$3.78M
$3.73M
$4.72M
Research and development
$6.2M
$3.89M
$12.35M
$4.55M
$5.45M
$7.14M
$5.14M
$4.31M
Total operating expenses
$9.76M
$8.01M
$16.94M
$8.13M
$8.74M
$10.93M
$8.87M
$9.03M
Operating income
-$9.76M
-$7.78M
-$16.94M
$10.52M
-$8.41M
-$9.56M
-$8.61M
-$8.05M
Interest expense
$0
$0
$0
$312K
$0
$0
-$485K
$1.05M
Income before taxes
-$8.46M
$7.4M
-$21.3M
$12.26M
-$8.59M
-$6.89M
-$5.39M
-$4.41M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$23K
Net income
-$8.46M
$7.4M
-$21.3M
$12.26M
-$8.59M
-$6.89M
-$5.39M
-$4.43M
Net income attributable to common shareholders
-$8.46M
$7.4M
-$21.3M
$12.26M
-$8.59M
-$6.89M
-$5.39M
-$4.43M
EBITDA
-$9.76M
-$7.78M
-$16.94M
$10.52M
-$8.41M
-$9.56M
-$8.61M
-$8.05M
Basic earnings per share
-$0.71
$0.63
-$3.36
$1.94
-$1.38
-$1.11
-$0.88
-$0.73
Diluted earnings per share
-$0.71
$0.63
-$3.36
$1.94
-$1.38
-$1.11
-$0.88
-$0.73
Recent news
Company coverage with links to the original publishers.
SCYNEXIS announced positive Phase 1 results for SCY-247, an intravenous antifungal candidate for invasive fungal diseases. The drug was well-tolerated with no serious adverse events, and doses of 50 mg or higher achieved target exposures identified in preclinical models. The company received a BARDA contract worth up to $214 million and plans to initiate Phase 2 studies in 2027 for both oral and IV formulations.
U.S. stock futures rose on Tuesday following Memorial Day, with the S&P 500 and Nasdaq 100 gaining 0.52% and 0.73% respectively. Despite U.S. defensive strikes on Iranian missile sites, markets remained resilient as oil prices fell and Iran negotiations progressed. Key movers included Elbit Systems jumping 8.26% on a $1.4B military contract, Intuitive Machines soaring 10.27% on a NASA lunar contract, and SCYNEXIS plunging 16.38% after announcing a reverse stock split.
SCYNEXIS, Inc. approved inducement equity awards for a new Vice President on April 30, 2026, consisting of stock options to purchase 125,000 shares at $0.93 per share and 20,000 restricted stock units. The awards were granted under the company's 2015 Inducement Award Plan in accordance with Nasdaq regulations.
SCYNEXIS announced the completion of its acquisition of PXL-770 (now SCY-770), a novel AMPK activator for treating ADPKD, the leading genetic cause of end-stage renal failure. Under the deal, SCYNEXIS will pay $8 million upfront with up to $188 million in potential milestone payments. The company plans to initiate a Phase 2 proof-of-concept study in Q4 2026 with early efficacy readout expected in H2 2027. SCY-770 has received FDA Orphan Drug Designation.
SCYNEXIS has transferred its BREXAFEMME New Drug Application to GSK, enabling potential regulatory interactions for relaunching the drug for vulvovaginal candidiasis. SCYNEXIS will receive potential net sales milestones and royalties from GSK.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.